Zydus Lifesciences Ltd. has received final nod from the United States Food and Drug Administration to manufacture 60 mg Apalutamide tablets, according to an exchange filing on Tuesday.

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

New research suggests that changes in alcohol consumption significantly impact cholesterol levels, raising questions about ...

MG’s relentless resurrection has come not only from competitively priced vehicles but a renewed commitment to clean, ...

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Tesla's anticipated arrival in India is stirring debate among industry leaders, with some expressing scepticism about its ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January ...

The positive trends at GIFT Nifty futures indicate a gap-up opening for Indian equity benchmarks Sensex and Nifty.

Results from Phase 2 RAINFOL TM -01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m 2 led to a confirmed objective response rate (ORR) of 55.6% and median ...

Longbow's starting price of £64,995 is less than half what the new Tesla Roadster will cost as Elon Musk's former employees ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objec ...